Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy

Robert A. Wermers, Kay Cooper, Raymund R Razonable, Paul J. Deziel, Gary M. Whitford, Walter K Kremers, Thomas P. Moyer

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels. Methods: To determine whether voriconazole is a cause of fluoride excess, we measured plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and 10 post-transplant patients who did not receive voriconazole. To assess the effect of renal insufficiency on fluoride levels in subjects receiving voriconazole, half were recruited on the basis of a serum creatinine level of ≥1.4 mg/dL on their most recent measurement, whereas the other 5 subjects receiving voriconazole had serum creatinine levels <1.4 mg/dL. All control subjects had serum creatinine levels of ≥1.4 mg/dL. Patients were excluded from the study if they received a fluorinated pharmaceutical other than voriconazole. Results: All subjects who received voriconazole had elevated plasma fluoride levels, and no subjects in the control group had elevated levels (14.32 μmol/L ± 6.41 vs 2.54 ± 0.67 lmol/L; P<.001). Renal function was not predictive of fluoride levels. Plasma fluoride levels remained significantly higher in the voriconazole group after adjusting for calcineurin inhibitor levels and doses. Half of the voriconazole group subjects had evidence of periostitis, including exostoses in 2 patients. Discontinuation of voriconazole therapy in patients with periostitis resulted in improvement of pain and a reduction in alkaline phosphatase and fluoride levels. Conclusions: Voriconazole is associated with painful periostitis, exostoses, and fluoride excess in posttransplant patients with long-term voriconazole use.

Original languageEnglish (US)
Pages (from-to)604-611
Number of pages8
JournalClinical Infectious Diseases
Volume52
Issue number5
DOIs
StatePublished - Mar 1 2011

Fingerprint

Periostitis
Fluorides
Transplants
Exostoses
Therapeutics
Creatinine
Voriconazole
Alkaline Phosphatase
Serum
Pain

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. / Wermers, Robert A.; Cooper, Kay; Razonable, Raymund R; Deziel, Paul J.; Whitford, Gary M.; Kremers, Walter K; Moyer, Thomas P.

In: Clinical Infectious Diseases, Vol. 52, No. 5, 01.03.2011, p. 604-611.

Research output: Contribution to journalArticle

Wermers, Robert A. ; Cooper, Kay ; Razonable, Raymund R ; Deziel, Paul J. ; Whitford, Gary M. ; Kremers, Walter K ; Moyer, Thomas P. / Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. In: Clinical Infectious Diseases. 2011 ; Vol. 52, No. 5. pp. 604-611.
@article{c6f533dfe396436299efc24b35d0fa2d,
title = "Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy",
abstract = "Background: We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels. Methods: To determine whether voriconazole is a cause of fluoride excess, we measured plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and 10 post-transplant patients who did not receive voriconazole. To assess the effect of renal insufficiency on fluoride levels in subjects receiving voriconazole, half were recruited on the basis of a serum creatinine level of ≥1.4 mg/dL on their most recent measurement, whereas the other 5 subjects receiving voriconazole had serum creatinine levels <1.4 mg/dL. All control subjects had serum creatinine levels of ≥1.4 mg/dL. Patients were excluded from the study if they received a fluorinated pharmaceutical other than voriconazole. Results: All subjects who received voriconazole had elevated plasma fluoride levels, and no subjects in the control group had elevated levels (14.32 μmol/L ± 6.41 vs 2.54 ± 0.67 lmol/L; P<.001). Renal function was not predictive of fluoride levels. Plasma fluoride levels remained significantly higher in the voriconazole group after adjusting for calcineurin inhibitor levels and doses. Half of the voriconazole group subjects had evidence of periostitis, including exostoses in 2 patients. Discontinuation of voriconazole therapy in patients with periostitis resulted in improvement of pain and a reduction in alkaline phosphatase and fluoride levels. Conclusions: Voriconazole is associated with painful periostitis, exostoses, and fluoride excess in posttransplant patients with long-term voriconazole use.",
author = "Wermers, {Robert A.} and Kay Cooper and Razonable, {Raymund R} and Deziel, {Paul J.} and Whitford, {Gary M.} and Kremers, {Walter K} and Moyer, {Thomas P.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1093/cid/ciq188",
language = "English (US)",
volume = "52",
pages = "604--611",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy

AU - Wermers, Robert A.

AU - Cooper, Kay

AU - Razonable, Raymund R

AU - Deziel, Paul J.

AU - Whitford, Gary M.

AU - Kremers, Walter K

AU - Moyer, Thomas P.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background: We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels. Methods: To determine whether voriconazole is a cause of fluoride excess, we measured plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and 10 post-transplant patients who did not receive voriconazole. To assess the effect of renal insufficiency on fluoride levels in subjects receiving voriconazole, half were recruited on the basis of a serum creatinine level of ≥1.4 mg/dL on their most recent measurement, whereas the other 5 subjects receiving voriconazole had serum creatinine levels <1.4 mg/dL. All control subjects had serum creatinine levels of ≥1.4 mg/dL. Patients were excluded from the study if they received a fluorinated pharmaceutical other than voriconazole. Results: All subjects who received voriconazole had elevated plasma fluoride levels, and no subjects in the control group had elevated levels (14.32 μmol/L ± 6.41 vs 2.54 ± 0.67 lmol/L; P<.001). Renal function was not predictive of fluoride levels. Plasma fluoride levels remained significantly higher in the voriconazole group after adjusting for calcineurin inhibitor levels and doses. Half of the voriconazole group subjects had evidence of periostitis, including exostoses in 2 patients. Discontinuation of voriconazole therapy in patients with periostitis resulted in improvement of pain and a reduction in alkaline phosphatase and fluoride levels. Conclusions: Voriconazole is associated with painful periostitis, exostoses, and fluoride excess in posttransplant patients with long-term voriconazole use.

AB - Background: We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels. Methods: To determine whether voriconazole is a cause of fluoride excess, we measured plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and 10 post-transplant patients who did not receive voriconazole. To assess the effect of renal insufficiency on fluoride levels in subjects receiving voriconazole, half were recruited on the basis of a serum creatinine level of ≥1.4 mg/dL on their most recent measurement, whereas the other 5 subjects receiving voriconazole had serum creatinine levels <1.4 mg/dL. All control subjects had serum creatinine levels of ≥1.4 mg/dL. Patients were excluded from the study if they received a fluorinated pharmaceutical other than voriconazole. Results: All subjects who received voriconazole had elevated plasma fluoride levels, and no subjects in the control group had elevated levels (14.32 μmol/L ± 6.41 vs 2.54 ± 0.67 lmol/L; P<.001). Renal function was not predictive of fluoride levels. Plasma fluoride levels remained significantly higher in the voriconazole group after adjusting for calcineurin inhibitor levels and doses. Half of the voriconazole group subjects had evidence of periostitis, including exostoses in 2 patients. Discontinuation of voriconazole therapy in patients with periostitis resulted in improvement of pain and a reduction in alkaline phosphatase and fluoride levels. Conclusions: Voriconazole is associated with painful periostitis, exostoses, and fluoride excess in posttransplant patients with long-term voriconazole use.

UR - http://www.scopus.com/inward/record.url?scp=79951828765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951828765&partnerID=8YFLogxK

U2 - 10.1093/cid/ciq188

DO - 10.1093/cid/ciq188

M3 - Article

C2 - 21239842

AN - SCOPUS:79951828765

VL - 52

SP - 604

EP - 611

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -